human epidermal development factor receptor, HER-epidermal growth factor receptor-tyrosine kinase inhibitors, EGFR-TKIsepidermal growth factor receptor, EGFRnon-small cell lung cancer, NSCLC bmutations were first-line treated with an oral administration of afatinib (40 mg/d) until disease progression. trials for confirmation. strong class=”kwd-title” Keywords: Afatinib, Epidermal growth factor receptor, Tyrosine kinase inhibitor, Lung neoplasms, Adverse event 85%non-small cell lung cancer, NSCLCNSCLC40%[1][2-4]EGFRepidermal growth factor receptor tyrosine kinase inhibitors, EGFR-TKIsEGFRNSCLCEGFR-TKIsAfatinib, Tomtovok, Tovok, BIBW 2992 1.? 1.1. 201011-20129LUX-Lung 6LUX-Lung 6b em EGFR /em 19L858R203L861QG719SG719AG719CT790MS768I18ECOG PS0135 13248-6359/32ECOG PS01141193L858R119L861Q 1 Characteristics, effect and survival conditions of all patients thead ?Patient 1Patient 2Patient 3Patient 4Patient 5 /thead tfoot ECOG: Eastern Cooperative Oncology Group; PS: performance status; PR: partial response; NK: not know; SD: stable disease; PD: progressive disease; PFS: progression-free survival; OS: overall survival; #: chest X ray showed lesion decreased; *: withdraw the trial because of other reason; **: withdraw the trial because of AZD-3965 ic50 mucositis/stomatitis. /tfoot GenderMaleFemaleFemaleMaleMaleAge (yr)5662635948Smoking statusSmokingNon-smokingNon-smokingEx-smokingSmokingStageECOG PS11011Type of EGFR mutationExon 19 deletion, AZD-3965 ic50 AZD-3965 ic50 L861QL858RL858RExon 19 deletionL858RThe best responsePRPRNK#SDPDPFS (month)NK9.7NK18.11.1OS (month)– *18.4– ** 29.53.4 Open in a separate window 1.2. 40 mg50 mg30 mg 1.3. CTC 3.0 1.4. RECIST 1.164812 1.5. 2progression-free survival, PFSoverall survival, OS 2.? 2.1. 2.1.1. 25100%480%/480%120% 2 Medication related adverse occasions of afatinib thead Adverse eventsGrade 1Grade 2Quality 3Total% /thead Gastrointestinal disorders???Diarrhea5005100??Nausea010120??Vomitting010120??Intestinal obstruction010120Skin and subcutaneous tissue disotders???Rash310480??Hand-foot skin response001120??Fingertip epidermis Rabbit Polyclonal to OR10J5 cracks100120Administration site circumstances and general disorders???Mucositis/stomatitis103480??Pharyngeal ulcer100120??Exhaustion100120??Fever100120Others???Paronychia010120??Facial edema100120??Palpitation100120 Open up in another window 2.1.2. 2/360%120%-severe adverse event, SAE/435 2.1.3. 1111479% 2.1.4. 360%2/1/1/2 2.2. 1 4full remission, CR0PR 250%goal response price, ORR250%SD 125%PD 125%1X 2.3. 1 2013833413PFS1.19.718.42PFS 9.72OS3.418.4129.52OS 18.4 3.? EGFR-TKIsEGFR[3, 4][4]EGFR-TKIs -HEREGFR-TKIsEGFR/HER-1HER-2HER-4[2, 5] [6]Yap[7]5310 mg-50 mg568%64%LUX-Lung 1[8]39050 mg87%/78%LUX-Lung 2[9]40 mg3097%/90%9950 mg94%/94%LUX-Lung 3[10]22940 mg95%/89%LUX-Lung 4[11]6250 mg100%/92%100%80%2 40 mg/80%Yap[7]40 mg23% em n /em =6LUX-Lung 2[9]40 mg50% em n /em =15LUX-Lung 2[9]LUX-Lung 4[11]50 mg90% em n /em =8986% em n /em =53LUX-Lung 3[10]3/72% em n /em =165LUX-Lung 1[8]50 mg61%/LUX-Lung 413%-94%Yap94%19%5[7-9, 11]50 mg40 mg/ [7, 9, 11]100%LUX-Lung 2[9] 79%[6] 360%LUX-Lung 1[8]38% em n /em =15018% em n /em =70LUX-Lung 2[9]40 mg37% em n /em AZD-3965 ic50 =11LUX-Lung 3[10]8%LUX-Lung 4[11]69% em n /em =4329% em n /em =1850 mg/[9-11]/LUX-Lung 4[11]23% SAELUX-Lung AZD-3965 ic50 1[8]10% em n /em =39174%92%LUX-Lung 2[9]12% em n /em =16LUX-Lung 3[10]42%211LUX-Lung 4[11]711%SAESAE EGFR-TKIsEGFR-TKIs[12-15]EGFR-TKIsEGFR-TKIsEGFR-TKIsEGFR-TKIs/EGFR-TKIsEGFR-TKIs[3]LUX-Lung 2[9]43%1LUX-Lung 3[10]31%LUX-Lung 4[11]23% LUX-Lung 6[16]/15%5%/5%[8-11] 54ORR 50%3PFSPFS 9.7LUX-Lung 6ORR 67%PFS 11.0LUX-Lung 3[10]PFS 11.1LUX-Lung 6LUX-Lung 3 em EGFR /em NSCLC3PFS21OS 18.4LUX-Lung 2OS 24.820.32.4PFSOS EGFR-TKI em EGFR /em /5.